432 related articles for article (PubMed ID: 17682796)
41. Current options for the management of postmenopausal osteoporosis.
Lecart MP; Reginster JY
Expert Opin Pharmacother; 2011 Nov; 12(16):2533-52. PubMed ID: 21916810
[TBL] [Abstract][Full Text] [Related]
42. Innovative interventions. What's new and what's ahead for osteoporosis.
Lebo S
Adv Nurse Pract; 2006 Sep; 14(9):43-6, 56. PubMed ID: 16972443
[No Abstract] [Full Text] [Related]
43. The effects of strontium ranelate in Asian women with postmenopausal osteoporosis.
Hwang JS; Chen JF; Yang TS; Wu DJ; Tsai KS; Ho C; Wu CH; Su SL; Wang CJ; Tu ST
Calcif Tissue Int; 2008 Nov; 83(5):308-14. PubMed ID: 18843436
[TBL] [Abstract][Full Text] [Related]
44. [Treatment of osteoporosis (with the exception of hormone replacement and its derivates].
Lamy O; Mischler C; Krieg MA
Rev Med Suisse Romande; 2002 Aug; 122(8):389-93. PubMed ID: 12357732
[TBL] [Abstract][Full Text] [Related]
45. Management of osteoporosis in Hong Kong.
Kung AW
Clin Calcium; 2004 Sep; 14(9):108-11. PubMed ID: 15577121
[TBL] [Abstract][Full Text] [Related]
46. [Strontium ranelate (Osseor)--unique double mechanism--physiologic bone treatment as live tissue].
Novak S
Reumatizam; 2007; 54(2):83-4. PubMed ID: 18351151
[No Abstract] [Full Text] [Related]
47. The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland.
Hiligsmann M; McGowan B; Bennett K; Barry M; Reginster JY
Value Health; 2012; 15(5):604-12. PubMed ID: 22867768
[TBL] [Abstract][Full Text] [Related]
48. [Treatment of osteoporosis from the socioeconomic perspectives].
Tanaka K
Clin Calcium; 2006 Sep; 16(9):1536-41. PubMed ID: 16951480
[TBL] [Abstract][Full Text] [Related]
49. No bones about it: preventing fractures.
Johns Hopkins Med Lett Health After 50; 2002 Mar; 14(1):4-5. PubMed ID: 14727597
[No Abstract] [Full Text] [Related]
50. Cost effectiveness and cost utility of risedronate for osteoporosis treatment and fracture prevention in women: a Swiss perspective.
Wasserfallen JB; Krieg MA; Greiner RA; Lamy O
J Med Econ; 2008; 11(3):499-523. PubMed ID: 19450101
[TBL] [Abstract][Full Text] [Related]
51. Strontium ranelate: new perspectives for the management of osteoporosis.
Cortet B
Rheumatology (Oxford); 2009 Oct; 48 Suppl 4():iv1-2. PubMed ID: 19783588
[No Abstract] [Full Text] [Related]
52. Cost-effectiveness of fracture prevention in established osteoporosis.
Jönsson B; Christiansen C; Johnell O; Hedbrandt J; Karlsson G
Scand J Rheumatol Suppl; 1996; 103():30-8; discussion 39-40. PubMed ID: 8966488
[TBL] [Abstract][Full Text] [Related]
53. [Osteoporosis in the elderly].
Retornaz F; Duque G
Presse Med; 2006 Oct; 35(10 Pt 2):1547-56. PubMed ID: 17028520
[TBL] [Abstract][Full Text] [Related]
54. No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial.
Anastasilakis AD; Goulis DG; Polyzos SA; Gerou S; Ballaouri I; Efstathiadou Z; Kita M; Avramidis A
Clin Endocrinol (Oxf); 2009 Apr; 70(4):522-6. PubMed ID: 18625000
[TBL] [Abstract][Full Text] [Related]
55. Osteoporosis: handy tools for detection, helpful tips for treatment.
Morgan SL; Kitchin B
J Fam Pract; 2008 May; 57(5):311-20. PubMed ID: 18460296
[No Abstract] [Full Text] [Related]
56. Cost effectiveness of hormone therapy in women at high risks of fracture in Sweden, the US and the UK--results based on the Women's Health Initiative randomised controlled trial.
Lekander I; Borgström F; Ström O; Zethraeus N; Kanis JA
Bone; 2008 Feb; 42(2):294-306. PubMed ID: 18053789
[TBL] [Abstract][Full Text] [Related]
57. Commentary on Mobley and Others: importance of assumptions about VTE mortality in modeling the cost-effectiveness of osteoporosis therapies.
Meadows ES; Stock J; Johnston JA
Med Decis Making; 2006; 26(6):633-5; author reply 636-7. PubMed ID: 17099202
[No Abstract] [Full Text] [Related]
58. The societal burden of osteoporosis in Sweden.
Borgström F; Sobocki P; Ström O; Jönsson B
Bone; 2007 Jun; 40(6):1602-9. PubMed ID: 17433804
[TBL] [Abstract][Full Text] [Related]
59. Strontium ranelate: the first agent of a new therapeutic class in osteoporosis.
Neuprez A; Hiligsmann M; Scholtissen S; Bruyere O; Reginster JY
Adv Ther; 2008 Dec; 25(12):1235-56. PubMed ID: 19066755
[TBL] [Abstract][Full Text] [Related]
60. [Primary osteoporosis--its diagnosis and treatment].
Inaba M
Nihon Rinsho; 2007 Nov; 65 Suppl 9():485-9. PubMed ID: 18161153
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
